Protocol Ledger

NCT03980925 · Phase II · COMPLETED

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Interventional Phase II clinical trial protocol NCT03980925 sponsored by Grupo Espanol de Tumores Neuroendocrinos in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-11 Enrollment: 37 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03980925
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)37 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03980925
Protocol FieldVerified Registry Value
NCT IdentifierNCT03980925
Consolidated Lead SponsorGrupo Espanol de Tumores Neuroendocrinos
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment37 participants (ACTUAL)
Registered Start Date2019-10-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI